Human medicines European public assessment report (EPAR): Vyvgart, efgartigimod alfa, Date of authorisation: 10/08/2022, Revision: 6, Status: Authorised

Human medicines European public assessment report (EPAR): Vyvgart, efgartigimod alfa, Date of authorisation: 10/08/2022, Revision: 6, Status: Authorised

Metadata
Provider: 
European Medicines AgencyEuropean Medicines Agency
URL: 
https://www.ema.europa.eu/en/medicines/human/EPAR/vyvgarthttps://www.ema.europa.eu/en/medicines/human/EPAR/vyvgart
Retrieved on: 
Tuesday, January 2, 2024
Information
Tags: 
Urine, Medical Subject Headings, Marketing, Protein, Acetylcholine receptor, Autoantibody, INN, GMG, Immune system, Fatigue, Lower respiratory tract infection, Infection, ATC, Antibody, International, Disease, Nose, Language, Blood, Muscle weakness, Urinary tract infection, Medicine, B cell, Neonatal Fc receptor, European Medicines Agency, Acetylcholine, Select, Patient, Anatomy, IIA, Medical device
Geotags: 
MG, EU
Summary
Key Points: 


Human medicines European public assessment report (EPAR): Vyvgart, efgartigimod alfa, Date of authorisation: 10/08/2022, Revision: 6, Status: Authorised

Copyright: 
2024 European Medicines Agency. All Rights Reserved.